Answers are grounded in this paper and cite their sources.
IN BRIEF The glucagon-like peptide-1 (GLP-1) receptor agonist class of medications has distinct benefits and limitations that provide an opportunity to individualize the treatment of patients with type 2 diabetes. Many strategies can be used to improve patient acceptance of and self-management with a GLP-1 receptor agonist.
No takes yet. Share an insight, caveat, or question.
Timothy Reid (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: